Why do clinicians worry about IGF-1 and cancer?
The worry is theoretical, and it comes from what these hormones do. Growth hormone and IGF-1 tell cells to grow and divide, which is how they build muscle and repair tissue. The same signal could, in principle, help a cancer that is already present grow faster. That is a reason for caution, not evidence that the peptides start cancers.
Drug labels treat the concern seriously. The somatropin (Genotropin) label says growth hormone is generally contraindicated in active malignancy and asks clinicians to monitor patients with a history of pituitary or brain tumors for progression or recurrence. The tesamorelin label goes further for its own drug: do not treat patients with active malignancy, and stop if there is any evidence of a cancer returning.
Sermorelin and tesamorelin raise IGF-1 by prompting your own pituitary to release more growth hormone. They work through the same pathway as growth hormone itself, so the same caution applies. Our page on the IGF-1 blood test for men explains how the level is measured and read.
What about healing peptides and blood-vessel growth?
Here the concern is angiogenesis, the formation of new blood vessels. The National Cancer Institute explains that solid tumors need a blood supply to grow beyond a few millimeters, and that signals such as VEGF drive new vessel growth. Some cancer treatments work by blocking those signals.
BPC-157 appears to push in the other direction. A 2025 systematic review of BPC-157 in sports medicine found studies suggesting it enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, with VEGF among the mediators. That is likely part of why it is studied for healing, and it is also why clinicians are wary of it in anyone with a known or suspected tumor.
What does the human data actually show?
Very little, in either direction. The table below summarizes where the evidence stands.
| Peptide | Theoretical concern | Human evidence on cancer |
|---|---|---|
| Sermorelin | Raises growth hormone and IGF-1 | Little long-term data in healthy men |
| Tesamorelin | Raises growth hormone and IGF-1 | Label rules out active malignancy and stops treatment on recurrence |
| BPC-157 | Growth and angiogenesis pathways | Review found 35 of 36 studies were in animals or cells, and no clinical safety data |
| TB-500 | Tissue repair signaling | FDA identified no human exposure data |
For TB-500, the FDA’s notes on compounding safety risks say it found no human exposure data at all. For BPC-157, the review’s single human study was a small retrospective report on knee pain. Neither tells you anything about cancer over years of use, which is the question that matters.
The clearest human cancer signal in this family comes from growth hormone itself, in a narrow group: the somatropin label notes a higher risk of a second tumor in childhood cancer survivors who had head or brain radiation and later received growth hormone. That is not the situation of a healthy adult man, but it shows why labels take the growth signal seriously.
Why does active cancer rule peptides out?
Because the downside is lopsided. If a growth or blood-vessel signal could help an existing tumor, the person with that tumor has the most to lose and nothing on the label to justify the risk. Both growth hormone labels draw the line at active malignancy, and the absence of safety data for BPC-157 and TB-500 gives no reason to treat them more loosely.
Anyone in active cancer treatment, or with a suspected cancer still being worked up, should not start these peptides. That includes an unexplained rising PSA; our page on the PSA blood test for men explains what prompts further evaluation.
What if you have a family history of cancer?
A family history is a reason to screen carefully, not an automatic stop. Your provider will look at which cancers ran in the family, at what ages, and whether you are up to date on the screening that fits your risk. Men with a family history of prostate cancer may be advised to start PSA testing earlier, regardless of any peptide decision.
How Ultimate Male screens for cancer risk before peptides
Every plan in our peptide therapy program starts with blood work, including IGF-1, metabolic and hormone markers, and a one-on-one consultation at San Gabriel or Downey where your personal and family cancer history is part of the review. An active malignancy means no peptide, and a past cancer means a careful conversation, sometimes with your oncologist.
Once a growth hormone peptide is started, IGF-1 is rechecked so it stays within your age range rather than drifting high. Our answer on peptide injection side effects covers what else is monitored. If a cancer history is the first thing on your mind, raise it on the free 10-minute call.
